镍过敏与血管内器械:系统综述与荟萃分析
该系统综述与荟萃分析检索MEDLINE和EMBASE(1947-2019),纳入78篇文献定性合成,15篇进入荟萃分析。斑贴试验证实的镍过敏与含镍血管内器械植入后不良结局风险升高相关(OR 2.61,95%CI 1.41-4.85),冠心病与结构性心脏病亚组亦显著,但神经血管亚组及患者自报镍过敏史不显著。
要点
- 斑贴试验证实的镍过敏增加含镍血管内器械植入后不良结局风险(OR 2.61)。
- 冠心病与结构性心脏病亚组风险显著升高,神经血管亚组不显著。
- 患者自报镍过敏史与不良结局关联不显著,建议行斑贴试验确诊。
核心结论
- 斑贴试验证实的镍过敏与血管内器械植入后不良结局风险升高相关,应考虑替代治疗方案。
- 对自报镍过敏的患者,专家应考虑进行诊断性斑贴试验。
研究设计与样本
- 系统综述与荟萃分析,采用随机效应模型。
- 检索MEDLINE和EMBASE 1947-2019年文献,识别190条记录,78篇纳入定性合成,15篇符合荟萃分析标准。
主要发现
- 斑贴试验证实的镍过敏与含镍血管内器械植入后不良结局风险升高相关(n=14篇,1740例患者;OR 2.61,95%CI 1.41-4.85)。
- 冠心病亚组中关联显著(n=12篇,1624例患者;OR 1.94,95%CI 1.16-3.23)。
- 结构性心脏病亚组中关联显著(n=2篇,83例患者;OR 52.28,95%CI 1.31-2079.14)。
- 神经血管亚组中关联不显著(n=1篇,33例患者;OR 3.04,95%CI 0.59-15.72)。
- 患者自报镍过敏史与不良结局关联不显著(n=2篇,207例患者;OR 2.14,95%CI 0.23-19.70)。
临床怎么用
- 对计划植入含镍血管内器械的患者,若怀疑镍过敏,应行斑贴试验确诊。
- 斑贴试验证实的镍过敏患者,应考虑替代治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Nickel allergy is common; endovascular specialists are often confronted with nickel allergic patients ahead of the implantation of endovascular devices, many of which are nickel-containing. Our aim was to elucidate whether nickel hypersensitivity is significantly associated with worse or adverse outcomes after placement of a nickel-containing endovascular device. METHODS: Inclusion criteria were: endovascular and transcatheter procedures for coronary, structural heart, neurovascular and peripheral vascular pathology involving nickel-allergic patients. All adverse outcomes were included as defined by included studies. A systematic review and meta-analysis were undertaken using a random-effects model. Searches of MEDLINE and EMBASE were conducted for articles published 1947-2019. RESULTS: 190 records were identified, 78 articles were included for qualitative synthesis and 15 met criteria for meta-analysis. Patch-test confirmed nickel allergy was associated with an increased risk of adverse outcomes following implantation of a nickel-containing endovascular device (n=14 articles, 1740 patients; OR 2.61, 95% CI 1.41 to 4.85). This finding further was observed in coronary (n=12 articles, 1624 patients; OR 1.94, 95% CI 1.16 to 3.23) and structural heart subgroups (n=2 articles, 83 patients; OR 52.28, 95% CI 1.31 to 2079.14), but not in the neurovascular subgroup (n=1 article, 33 patients; OR 3.04, 95% CI 0.59 to 15.72) or with a patient-reported history of nickel allergy (n=2 articles, 207 patients; OR 2.14, 95% CI 0.23 to 19.70). CONCLUSIONS: Patch-tested nickel allergy is associated with an increased risk of adverse outcomes following endovascular device implantation and alternative treatment options should be considered. Specialists faced with patients' self-reporting nickel allergy should consider proceeding to diagnostic patch-testing.
引用
- Guéroult AM, Al-Balah A, Davies AH, et al. Nickel hypersensitivity and endovascular devices: a systematic review and meta-analysis. Heart. 2022. PMID: 34702756. doi:10.1136/heartjnl-2021-319940
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。